Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy
Authors:
- Henry EkertHEHenry Ekert
- Christian BrizardCBChristian Brizard
- Robert EyersRERobert Eyers
- Andrew CochraneACAndrew Cochrane
- Robert HenningRHRobert Henning
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 17 (5) , 389-395
Abstract
We investigated the effectiveness of prophylactic administration of recombinant activated factor VII (rFVIIa) for cardiopulmonary bypass surgery in children under 1 year old with congenital heart disease (CHD) in a double-blinded, placebo-controlled study. The rFVIIa dose was 40 μg/kg and all patients also received standard haemostatic replacement therapy. The primary endpoint was the time to chest closure from neutralization of heparin with protamine sulphate as this could be most objectively and accurately measured during surgery. Secondary endpoints were volumes of transfused blood, platelet concentrates and fresh-frozen plasma. All adverse events were recorded. In the intention-to-treat analysis there were 76 patients (40 in rFVIIa group and 36 in placebo group). The demographics and severity of CHD were similar in both groups. No benefit of rFVIIa prophylaxis was found in the time to chest closure, which was significantly prolonged in the rFVIIa group (rFVIIa mean ± SE, 98.8 ± 27.27 versus 55.3 ± 29.15, P = 0.0263). In the 41 patients available for a follow-up visit 6 weeks after discharge, the chest closure time was also prolonged in the rFVIIa group (P = 0.0515). There were no significant differences in the secondary endpoints. Adverse events were similar in both groups.Keywords
This publication has 15 references indexed in Scilit:
- Recombinant factor VIIa to treat bleeding after cardiac surgery in an infantPediatric Critical Care Medicine, 2003
- Preliminary Experience with the Use of Recombinant Factor VIIa to Treat Coagulation Disturbances in Pediatric PatientsSouthern Medical Journal, 2003
- Ongoing NovoSeven ® trialsIntensive Care Medicine, 2002
- Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfectaThe Annals of Thoracic Surgery, 2002
- Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist deviceThe Journal of Thoracic and Cardiovascular Surgery, 2002
- An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VIIAnesthesia & Analgesia, 2001
- Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgeryBlood Coagulation & Fibrinolysis, 2000
- Mediastinal Bleeding After Cardiopulmonary Bypass in Pediatric PatientsThe Annals of Thoracic Surgery, 1996
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 1994
- RETRACTED: Aprotinin in pediatric cardiac operations: Platelet function, blood loss, and use of homologous bloodThe Annals of Thoracic Surgery, 1993